nach oben

Clinical and Translational Oncology

Erschienen in:

31.10.2022 | Review Article

Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials

verfasst von: Shuai Xiao, Guo Huang, Weihong Zeng, Jun Zhou, Yukun Li, Tingyu Fan, Xiaomin Liu, Jiliang Xia, Xi Zeng

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer (EC) in Asia. It is a malignant digestive tract tumor with abundant gene mutations. Due to the lack of specific diagnostic markers and early cancer screening markers, most patients are diagnosed at an advanced stage. Genetic and epigenetic changes are closely related to the occurrence and development of ESCC. Here, We review the activation of proto-oncogenes into oncogenes through gene mutation and gene amplification in ESCC from a genetic and epigenetic genome perspective, We also discuss the specific regulatory mechanisms through which these oncogenes mainly affect the biological function and occurrence and development of ESCC through specific regulatory mechanisms. In addition, we summarize the clinical application value of these oncogenes is summarized, and it provides a feasible direction for clinical use as potential therapeutic and diagnostic markers.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–5. https://doi.org/10.1038/nature13176.CrossRefPubMed

Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000–2013. Cancer Med. 2019;8(11):5158–72. https://doi.org/10.1002/cam4.2451.CrossRefPubMedPubMedCentral

Liu X, Zhang M, Ying S, Zhang C, Lin R, Zheng J, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology. 2017;153(1):166–77. https://doi.org/10.1053/j.gastro.2017.03.033.CrossRefPubMed

Lima SC, Hernandez-Vargas H, Simao T, Durand G, Kruel CD, Le Calvez-Kelm F, et al. Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics. 2011;6(10):1217–27. https://doi.org/10.4161/epi.6.10.17199.CrossRefPubMed

O’Reilly S, Forastiere AA. Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol. 1995;6(6):519–21. https://doi.org/10.1093/oxfordjournals.annonc.a059237.CrossRefPubMed

Wu J, Yang J, Lin X, Lin L, Jiang W, Xie C. Survival outcomes for patients with four treatments in stages I-III esophageal squamous cell carcinoma: a SEER analysis. Transl Cancer Res. 2021;10(5):2144–52. https://doi.org/10.21037/tcr-20-2995.CrossRefPubMedPubMedCentral

Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009–15. https://doi.org/10.21873/anticanres.14622.CrossRefPubMed

Balmain A, Brown K. Oncogene activation in chemical carcinogenesis. Amsterdam: Elsevier; 1988. p. 147–82.

10.

Gebhart E, Liehr T. Patterns of genomic imbalances in human solid tumors (Review). Int J Oncol. 2000;16(2):383–99. https://doi.org/10.3892/ijo.16.2.383.CrossRefPubMed

11.

Wang L, Shan L, Zhang S, Ying J, Xue L, Yuan Y, et al. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. PLoS ONE. 2014;9(7):e103021. https://doi.org/10.1371/journal.pone.0103021.CrossRefPubMedPubMedCentral

12.

Munari FF, Cruvinel-Carloni A, Lacerda CF, de Oliveira ATT, Scapulatempo-Neto C, da Silva SRM, et al. PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome. Infect Agent Cancer. 2018;13:43. https://doi.org/10.1186/s13027-018-0216-3.CrossRefPubMedPubMedCentral

13.

Gu Y, Lin X, Kapoor A, Chow MJ, Jiang Y, Zhao K, et al. The oncogenic potential of the centromeric border protein FAM84B of the 8q24.21 gene desert. Genes. 2020. https://doi.org/10.3390/genes11030312.CrossRefPubMedPubMedCentral

14.

Zhang Q, Zhao X, Zhang C, Wang W, Li F, Liu D, et al. Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma. Cancer Manag Res. 2019;11:7813–24. https://doi.org/10.2147/CMAR.S214243.CrossRefPubMedPubMedCentral

15.

Dong D, Zhang W, Xiao W, Wu Q, Cao Y, Gao X, et al. A GRN autocrine-dependent FAM135B/AKT/mTOR feedforward loop promotes esophageal squamous cell carcinoma progression. Cancer Res. 2021;81(4):910–22. https://doi.org/10.1158/0008-5472.CAN-20-0912.CrossRefPubMed

16.

Peng C, Song Y, Chen W, Wang X, Liu X, Wang F, et al. FLVCR1 promotes the proliferation and tumorigenicity of synovial sarcoma through inhibiting apoptosis and autophagy. Int J Oncol. 2018;52(5):1559–68. https://doi.org/10.3892/ijo.2018.4312.CrossRefPubMed

17.

Kong L, Yu Y, Guan H, Jiang L, Sun F, Li X, et al. TGIF1 plays a carcinogenic role in esophageal squamous cell carcinoma through the Wnt/β-catenin and Akt/mTOR signaling pathways. Int J Mol Med. 2021. https://doi.org/10.3892/ijmm.2021.4910.CrossRefPubMedPubMedCentral

18.

Zhang H, Qin G, Zhang C, Yang H, Liu J, Hu H, et al. TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas. J Exp Clin Cancer Res. 2021;40(1):209. https://doi.org/10.1186/s13046-021-01972-0.CrossRefPubMedPubMedCentral

19.

Wang X, Ge X, Wang H, Huang J, Song Q, Xu C, et al. SOX2 amplification and chromosome 3 gain significantly impact prognosis in esophageal squamous cell carcinoma. Ann Transl Med. 2021;9(4):321. https://doi.org/10.21037/atm-20-1290.CrossRefPubMedPubMedCentral

20.

Bi Y, Kong P, Zhang L, Cui H, Xu X, Chang F, et al. EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinoma. J Cancer. 2019;10(22):5413–26. https://doi.org/10.7150/jca.34261.CrossRefPubMedPubMedCentral

21.

Abudureheman A, Ainiwaer J, Hou Z, Niyaz M, Turghun A, Hasim A, et al. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2018;144(6):1025–35. https://doi.org/10.1007/s00432-018-2625-5.CrossRefPubMedPubMedCentral

22.

Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38. https://doi.org/10.1038/npp.2012.112.CrossRefPubMed

23.

Teng H, Xue M, Liang J, Wang X, Wang L, Wei W, et al. Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma. Theranostics. 2020;10(7):3035–48. https://doi.org/10.7150/thno.42559.CrossRefPubMedPubMedCentral

24.

Zhang L, Lu Q, Chang C. Epigenetics in health and disease. Adv Exp Med Biol. 2020;1253:3–55. https://doi.org/10.1007/978-981-15-3449-2_1.CrossRefPubMed

25.

Lin L, Cheng X, Yin D. Aberrant DNA methylation in esophageal squamous cell carcinoma: biological and clinical implications. Front Oncol. 2020;10:549850. https://doi.org/10.3389/fonc.2020.549850.CrossRefPubMedPubMedCentral

26.

Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303. https://doi.org/10.1038/nature10351.CrossRefPubMedPubMedCentral

27.

Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830–7. https://doi.org/10.1038/ng.892.CrossRefPubMedPubMedCentral

28.

Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400–4. https://doi.org/10.1038/nature11017.CrossRefPubMedPubMedCentral

29.

Li H, Li Q, Lian J, Chu Y, Fang K, Xu A, et al. MLL2 promotes cancer cell lymph node metastasis by interacting with RelA and facilitating STC1 transcription. Cell Signal. 2020;65:109457. https://doi.org/10.1016/j.cellsig.2019.109457.CrossRefPubMed

30.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–7. https://doi.org/10.1126/science.1840703.CrossRefPubMed

31.

Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, et al. Melanoma-associated antigen genes—an update. Cancer Lett. 2011;302(2):85–90. https://doi.org/10.1016/j.canlet.2010.10.021.CrossRefPubMed

32.

Sang M, Lian Y, Zhou X, Shan B. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine. 2011;29(47):8496–500. https://doi.org/10.1016/j.vaccine.2011.09.014.CrossRefPubMed

33.

Gu L, Sang M, Li J, Liu F, Wu Y, Liu S, et al. Demethylation-mediated upregulation of melanoma-associated antigen-A11 correlates with malignant progression of esophageal squamous cell carcinoma. Dig Liver Dis. 2019;51(10):1475–82. https://doi.org/10.1016/j.dld.2019.04.018.CrossRefPubMed

34.

Liu S, Liu F, Huang W, Gu L, Meng L, Ju Y, et al. MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth. Oncotarget. 2018;9(3):3365–78. https://doi.org/10.18632/oncotarget.22973.CrossRefPubMed

35.

Sang M, Gu L, Liu F, Lian Y, Yin D, Fan X, et al. Prognostic significance of MAGE-A11 in esophageal squamous cell carcinoma and identification of related genes based on DNA microarray. Arch Med Res. 2016;47(3):151–61. https://doi.org/10.1016/j.arcmed.2016.06.001.CrossRefPubMed

36.

Boccaletto P, Baginski B. MODOMICS: an operational guide to the use of the RNA modification pathways database. Methods Mol Biol. 2021;2284:481–505. https://doi.org/10.1007/978-1-0716-1307-8_26.CrossRefPubMed

37.

Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103. https://doi.org/10.1186/s12943-019-1033-z.CrossRefPubMedPubMedCentral

38.

Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19(1):88. https://doi.org/10.1186/s12943-020-01204-7.CrossRefPubMedPubMedCentral

39.

Mendel M, Delaney K, Pandey RR, Chen KM, Wenda JM, Vagbo CB, et al. Splice site m(6)A methylation prevents binding of U2AF35 to inhibit RNA splicing. Cell. 2021;184(12):3125-3142 e25.CrossRefPubMedPubMedCentral

40.

Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149(7):1635–46. https://doi.org/10.1016/j.cell.2012.05.003.CrossRefPubMedPubMedCentral

41.

Kataoka H, Sekiguchi M. Molecular cloning and characterization of the alkB gene of Escherichia coli. Mol Gen Genet. 1985;198(2):263–9. https://doi.org/10.1007/bf00383004.CrossRefPubMed

42.

Liu Y, Yuan Q, Xie L. The AlkB family of Fe (II)/alpha-ketoglutarate-dependent dioxygenases modulates embryogenesis through epigenetic regulation. Curr Stem Cell Res Ther. 2018. https://doi.org/10.2174/1574888x12666171027105532.CrossRefPubMed

43.

Kurowski MA, Bhagwat AS, Papaj G, Bujnicki JM. Phylogenomic identification of five new human homologs of the DNA repair enzyme AlkB. BMC Genomics. 2003;4(1):48. https://doi.org/10.1186/1471-2164-4-48.CrossRefPubMedPubMedCentral

44.

Xue J, Xiao P, Yu X, Zhang X. A positive feedback loop between AlkB homolog 5 and miR-193a-3p promotes growth and metastasis in esophageal squamous cell carcinoma. Hum Cell. 2021;34(2):502–14. https://doi.org/10.1007/s13577-020-00458-z.CrossRefPubMed

45.

Liu S, Huang M, Chen Z, Chen J, Chao Q, Yin X, et al. FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020;389(1):111894. https://doi.org/10.1016/j.yexcr.2020.111894.CrossRefPubMed

46.

Cui Y, Zhang C, Ma S, Li Z, Wang W, Li Y, et al. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2021;40(1):294. https://doi.org/10.1186/s13046-021-02096-1.CrossRefPubMedPubMedCentral

47.

Gao R, Ye M, Liu B, Wei M, Ma D, Dong K. m6A Modification: a double-edged sword in tumor development. Front Oncol. 2021;11:679367. https://doi.org/10.3389/fonc.2021.679367.CrossRefPubMedPubMedCentral

48.

Han H, Yang C, Zhang S, Cheng M, Guo S, Zhu Y, et al. METTL3-mediated m(6)A mRNA modification promotes esophageal cancer initiation and progression via notch signaling pathway. Mol Ther Nucleic Acids. 2021;26:333–46. https://doi.org/10.1016/j.omtn.2021.07.007.CrossRefPubMedPubMedCentral

49.

Chen X, Huang L, Yang T, Xu J, Zhang C, Deng Z, et al. METTL3 promotes esophageal squamous cell carcinoma metastasis through enhancing GLS2 expression. Front Oncol. 2021;11:667451. https://doi.org/10.3389/fonc.2021.667451.CrossRefPubMedPubMedCentral

50.

Liu Z, Wu K, Gu S, Wang W, Xie S, Lu T, et al. A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. Clin Transl Med. 2021;11(9):e545. https://doi.org/10.1002/ctm2.545.CrossRefPubMedPubMedCentral

51.

Xu LC, Pan JX, Pan HD. Construction and validation of an m6A RNA methylation regulators-based prognostic signature for esophageal cancer. Cancer Manag Res. 2020;12:5385–94. https://doi.org/10.2147/CMAR.S254870.CrossRefPubMedPubMedCentral

52.

Zhang X, Lu N, Wang L, Wang Y, Li M, Zhou Y, et al. Recent advances of m(6)A methylation modification in esophageal squamous cell carcinoma. Cancer Cell Int. 2021;21(1):421. https://doi.org/10.1186/s12935-021-02132-2.CrossRefPubMedPubMedCentral

53.

Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2(10):a003236. https://doi.org/10.1101/cshperspect.a003236.CrossRefPubMedPubMedCentral

54.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. https://doi.org/10.1016/j.cell.2012.03.017.CrossRefPubMedPubMedCentral

55.

Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–89. https://doi.org/10.1007/82_2017_6.CrossRefPubMed

56.

Wang L, Zhang Z, Yu X, Li Q, Wang Q, Chang A, et al. SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression. Cancer Lett. 2020;468:14–26. https://doi.org/10.1016/j.canlet.2019.10.004.CrossRefPubMed

57.

Gen Y, Yasui K, Nishikawa T, Yoshikawa T. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci. 2013;104(7):810–6. https://doi.org/10.1111/cas.12155.CrossRefPubMedPubMedCentral

58.

Arechavaleta-Velasco F, Perez-Juarez CE, Gerton GL, Diaz-Cueto L. Progranulin and its biological effects in cancer. Med Oncol. 2017;34(12):194. https://doi.org/10.1007/s12032-017-1054-7.CrossRefPubMedPubMedCentral

59.

Yang D, Li R, Wang H, Wang J, Han L, Pan L, et al. Clinical implications of progranulin in gastric cancer and its regulation via a positive feedback loop involving AKT and ERK signaling pathways. Mol Med Rep. 2017;16(6):9685–91. https://doi.org/10.3892/mmr.2017.7796.CrossRefPubMed

60.

Feng T, Zheng L, Liu F, Xu X, Mao S, Wang X, et al. Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway. Oncotarget. 2016;7(36):58381–95. https://doi.org/10.18632/oncotarget.11126.CrossRefPubMedPubMedCentral

61.

Wang C, Cheng L, Song S, Wu S, Sun G. Gli1 interacts with YAP1 to promote tumorigenesis in esophageal squamous cell carcinoma. J Cell Physiol. 2020;235(11):8224–35. https://doi.org/10.1002/jcp.29477.CrossRefPubMed

62.

Rizvi S, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, et al. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res. 2010;70(17):6787–96. https://doi.org/10.1158/0008-5472.Can-10-0197.CrossRefPubMedPubMedCentral

63.

Wei L, Xu Z. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer. 2011;129(2):275–84. https://doi.org/10.1002/ijc.25673.CrossRefPubMed

64.

Yang Z, Cui Y, Ni W, Kim S, Xuan Y. Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017;143(2):243–54. https://doi.org/10.1007/s00432-016-2273-6.CrossRefPubMed

65.

Maehama T, Nishio M, Otani J, Mak TW, Suzuki A. The role of Hippo-YAP signaling in squamous cell carcinomas. Cancer Sci. 2021;112(1):51–60. https://doi.org/10.1111/cas.14725.CrossRefPubMed

66.

Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt/beta-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307. https://doi.org/10.1038/s41392-021-00701-5.CrossRefPubMedPubMedCentral

67.

Koni M, Pinnaro V, Brizzi MF. The Wnt signalling pathway: a tailored target in cancer. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21207697.CrossRefPubMedPubMedCentral

68.

Zhang Y, Wang X. Targeting the Wnt/beta-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165. https://doi.org/10.1186/s13045-020-00990-3.CrossRefPubMedPubMedCentral

69.

Lv Z, Liu RD, Chen XQ, Wang B, Li LF, Guo YS, et al. HIF1alpha promotes the stemness of oesophageal squamous cell carcinoma by activating the Wnt/betacatenin pathway. Oncol Rep. 2019;42(2):726–34. https://doi.org/10.3892/or.2019.7203.CrossRefPubMed

70.

Gou Y, Jin D, He S, Han S, Bai Q. RNF168 is highly expressed in esophageal squamous cell carcinoma and contributes to the malignant behaviors in association with the Wnt/β-catenin signaling pathway. Aging. 2021;13(4):5403–14. https://doi.org/10.18632/aging.202471.CrossRefPubMedPubMedCentral

71.

Tang Y, Yang P, Zhu Y, Su Y. LncRNA TUG1 contributes to ESCC progression via regulating miR-148a-3p/MCL-1/Wnt/β-catenin axis in vitro. Thorac Cancer. 2020;11(1):82–94. https://doi.org/10.1111/1759-7714.13236.CrossRefPubMed

72.

Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21–45. https://doi.org/10.1016/j.cell.2016.06.028.CrossRefPubMed

73.

Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, et al. Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett. 2012;325(1):42–53. https://doi.org/10.1016/j.canlet.2012.05.024.CrossRefPubMed

74.

De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110. https://doi.org/10.1038/nrc3447.CrossRefPubMed

75.

Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488–94. https://doi.org/10.1038/ncb2976.CrossRefPubMed

76.

Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81. https://doi.org/10.1016/j.canlet.2019.10.013.CrossRefPubMed

77.

Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26. https://doi.org/10.1016/j.tcb.2018.12.001.CrossRefPubMed

78.

Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X, et al. High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91(5):1531–8. https://doi.org/10.1016/j.athoracsur.2010.12.012.CrossRefPubMed

79.

Razzaque MS, Atfi A. TGIF function in oncogenic Wnt signaling. Biochim Biophys Acta. 2016;1865(2):101–4. https://doi.org/10.1016/j.bbcan.2015.10.003.CrossRefPubMed

80.

Zhang MZ, Ferrigno O, Wang Z, Ohnishi M, Prunier C, Levy L, et al. TGIF governs a feed-forward network that empowers Wnt signaling to drive mammary tumorigenesis. Cancer Cell. 2015;27(4):547–60. https://doi.org/10.1016/j.ccell.2015.03.002.CrossRefPubMedPubMedCentral

81.

Wang L, Liu G, Bolor-Erdene E, Li Q, Mei Y, Zhou L. Identification of KIF4A as a prognostic biomarker for esophageal squamous cell carcinoma. Aging. 2021;13(21):24050–70. https://doi.org/10.18632/aging.203585.CrossRefPubMedPubMedCentral

82.

Guo X, Zhu R, Luo A, Zhou H, Ding F, Yang H, et al. EIF3H promotes aggressiveness of esophageal squamous cell carcinoma by modulating snail stability. J Exp Clin Cancer Res. 2020;39(1):175. https://doi.org/10.1186/s13046-020-01678-9.CrossRefPubMedPubMedCentral

83.

Ma S, Meng Z, Chen R, Guan KL. The hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577–604. https://doi.org/10.1146/annurev-biochem-013118-111829.CrossRefPubMed

84.

Sun X, Chen P, Chen X, Yang W, Chen X, Zhou W, et al. KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma. Thorac Cancer. 2021;12(4):512–24. https://doi.org/10.1111/1759-7714.13787.CrossRefPubMed

85.

Zhou X, Li Y, Wang W, Wang S, Hou J, Zhang A, et al. Regulation of hippo/YAP signaling and esophageal squamous carcinoma progression by an E3 ubiquitin ligase PARK2. Theranostics. 2020;10(21):9443–57. https://doi.org/10.7150/thno.46078.CrossRefPubMedPubMedCentral

86.

Pang D, Wang W, Zhou X, Lu K, Zhang J, Chen Z, et al. RACO-1 modulates hippo signalling in oesophageal squamous cell carcinoma. J Cell Mol Med. 2020;24(20):11912–21. https://doi.org/10.1111/jcmm.15811.CrossRefPubMedPubMedCentral

87.

Zhang J, Wang JL, Zhang CY, Ma YF, Zhao R, Wang YY. The prognostic role of FZD6 in esophageal squamous cell carcinoma patients. Clin Transl Oncol. 2020;22(7):1172–9. https://doi.org/10.1007/s12094-019-02243-3.CrossRefPubMed

88.

Jia J, Li H, Chu J, Sheng J, Wang C, Jia Z, et al. LncRNA FAM83A-AS1 promotes ESCC progression by regulating miR-214/CDC25B axis. J Cancer. 2021;12(4):1200–11. https://doi.org/10.7150/jca.54007.CrossRefPubMedPubMedCentral

89.

Zhang H, Wang Y, Zhang W, Wu Q, Fan J, Zhan Q. BAALC-AS1/G3BP2/c-Myc feedback loop promotes cell proliferation in esophageal squamous cell carcinoma. Cancer Commun. 2021;41(3):240–57. https://doi.org/10.1002/cac2.12127.CrossRef

90.

Zhao Z, Yang S, Zhou A, Li X, Fang R, Zhang S, et al. Small extracellular vesicles in the development, diagnosis, and possible therapeutic application of esophageal squamous cell carcinoma, front. Oncol. 2021;11: 732702. https://doi.org/10.3389/fonc.2021.732702.CrossRef

91.

Tong Y, Yang L, Yu C, Zhu W, Zhou X, Xiong Y, et al. Tumor-secreted exosomal lncRNA POU3F3 promotes cisplatin resistance in ESCC by inducing fibroblast differentiation into CAFs. Mol Ther Oncolytics. 2020;18:1–13. https://doi.org/10.1016/j.omto.2020.05.014.CrossRefPubMedPubMedCentral

92.

Shi S, Huang X, Ma X, Zhu X, Zhang Q. Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells. PLoS ONE. 2020;15(5):e0225290. https://doi.org/10.1371/journal.pone.0225290.CrossRefPubMedPubMedCentral

93.

Yang YC, Liu GJ, Yuan DF, Li CQ, Xue M, Chen LJ. Influence of exosome-derived miR-21on chemotherapy resistance of esophageal cancer. Eur Rev Med Pharmacol Sci. 2019;23(4):1513–9. https://doi.org/10.26355/eurrev_201902_17109.CrossRefPubMed

94.

Liu T, Li P, Li J, Qi Q, Sun Z, Shi S, et al. Exosomal and intracellular miR-320b promotes lymphatic metastasis in esophageal squamous cell carcinoma. Molecular Therapy - Oncolytics. 2021;23:163–80. https://doi.org/10.1016/j.omto.2021.09.003.CrossRefPubMedPubMedCentral

95.

Goto M, Liu M. Chemokines and their receptors as biomarkers in esophageal cancer. Esophagus. 2020;17(2):113–21. https://doi.org/10.1007/s10388-019-00706-8.CrossRefPubMed

96.

Inoue S, Yoshida T, Nishino T, Goto M, Aoyama M, Kawakita N, et al. Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg. 2021;69(3):525–33. https://doi.org/10.1007/s11748-021-01586-5.CrossRefPubMed

97.

Murugan AK, Munirajan AK, Tsuchida N. Genetic deregulation of the PIK3CA oncogene in oral cancer. Cancer Lett. 2013;338(2):193–203. https://doi.org/10.1016/j.canlet.2013.04.005.CrossRefPubMed

98.

Suzuki H, Wang L, Shan L, Zhang S, Ying J, Xue L, et al. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in chinese esophageal squamous cell carcinoma. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0103021.CrossRefPubMedPubMedCentral

99.

Zheng S, Yang C, Lu M, Liu Q, Liu T, Dai F, et al. PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma. Hum Pathol. 2016;53:121–9. https://doi.org/10.1016/j.humpath.2015.11.013.CrossRefPubMed

100.

Chen P, Zhang Z, Chen X. Overexpression of PKMYT1 facilitates tumor development and is correlated with poor prognosis in clear cell renal cell carcinoma. Med Sci Monit. 2020;26:e926755. https://doi.org/10.12659/msm.926755.CrossRefPubMedPubMedCentral

101.

Asquith CRM, Laitinen T, East MP. PKMYT1: a forgotten member of the WEE1 family. Nat Rev Drug Discov. 2020;19(3):157. https://doi.org/10.1038/d41573-019-00202-9.CrossRefPubMed

102.

Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 2019;178(2):330-345.e22. https://doi.org/10.1016/j.cell.2019.06.005.CrossRefPubMed

103.

Sohoni S, Ghosh P, Wang T, Kalainayakan SP, Vidal C, Dey S, et al. Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells. Cancer Res. 2019;79(10):2511–25. https://doi.org/10.1158/0008-5472.Can-18-2156.CrossRefPubMed

104.

Zhou S, Zhang M, Zhou C, Meng Y, Yang H, Ye W. FLVCR1 predicts poor prognosis and promotes malignant phenotype in esophageal squamous cell carcinoma via upregulating CSE1L. Front Oncol. 2021;11:660955. https://doi.org/10.3389/fonc.2021.660955.CrossRefPubMedPubMedCentral

105.

Hsu FM, Cheng JC, Chang YL, Lee JM, Koong AC, Chuang EY. Circulating mRNA Profiling in esophageal squamous cell carcinoma identifies FAM84B As A biomarker in predicting pathological response to neoadjuvant chemoradiation. Sci Rep. 2015;5:10291. https://doi.org/10.1038/srep10291.CrossRefPubMedPubMedCentral

106.

Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst. 2008;100(13):962–6. https://doi.org/10.1093/jnci/djn190.CrossRefPubMedPubMedCentral

107.

Huang XP, Rong TH, Wang JY, Tang YQ, Li BJ, Xu DR, et al. Negative implication of C-MYC as an amplification target in esophageal cancer. Cancer Genet Cytogenet. 2006;165(1):20–4. https://doi.org/10.1016/j.cancergencyto.2005.07.009.CrossRefPubMed

108.

Cheng C, Cui H, Zhang L, Jia Z, Song B, Wang F, et al. Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. Gigascience. 2016;5:1. https://doi.org/10.1186/s13742-015-0107-0.CrossRefPubMedPubMedCentral

109.

Zheng YJ, Liang TS, Wang J, Zhao JY, Zhai SN, Yang DK, et al. MicroRNA-155 acts as a diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Artif Cells Nanomed Biotechnol. 2020;48(1):977–82. https://doi.org/10.1080/21691401.2020.1773479.CrossRefPubMed

110.

Shiromoto Y, Sakurai M, Minakuchi M, Ariyoshi K, Nishikura K. ADAR1 RNA editing enzyme regulates R-loop formation and genome stability at telomeres in cancer cells. Nat Commun. 2021;12(1):1654. https://doi.org/10.1038/s41467-021-21921-x.CrossRefPubMedPubMedCentral

111.

Qiao JJ, Chan TH, Qin YR, Chen L. ADAR1: a promising new biomarker for esophageal squamous cell carcinoma? Expert Rev Anticancer Ther. 2014;14(8):865–8. https://doi.org/10.1586/14737140.2014.928595.CrossRefPubMed

112.

Wang T, Lv X, Jiang S, Han S, Wang Y. Expression of ADAM29 and FAM135B in the pathological evolution from normal esophageal epithelium to esophageal cancer: their differences and clinical significance. Oncol Lett. 2020;19(3):1727–34. https://doi.org/10.3892/ol.2020.11272.CrossRefPubMedPubMedCentral

113.

Lu YF, Yu JR, Yang Z, Zhu GX, Gao P, Wang H, et al. Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC). J Exp Clin Cancer Res. 2018;37(1):301. https://doi.org/10.1186/s13046-018-0966-1.CrossRefPubMedPubMedCentral

114.

Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49(5):412–20. https://doi.org/10.1093/jjco/hyz034.CrossRefPubMed

Titel: Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials
verfasst von: Shuai Xiao
Guo Huang
Weihong Zeng
Jun Zhou
Yukun Li
Tingyu Fan
Xiaomin Liu
Jiliang Xia
Xi Zeng
Publikationsdatum: 31.10.2022
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 3/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-022-02981-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

CD155 is a putative therapeutic target in medulloblastoma

Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy

The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma

Leptin signaling in breast cancer and its crosstalk with peroxisome proliferator-activated receptors α and γ

Haematological and renal toxicity of radiation therapy in neuroblastoma paediatric patients

Acknowledgement to reviewers 2022

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie